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The Neurorestoratology discipline is getting worldwide attention from the clinicians,
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basic scientists, students and policy makers alike. Accordingly, this year too, the
discipline has made profound advances and great achievements for the benefit of the
mankind. In this report, of the 2018 Neurorestoratology Yearbook, salient features of
new developments are summarized. This Yearbook consists 3 key themes namely (i) the
new findings on pathogenesis of neurological diseases or degeneration; (ii) the new
mechanisms of neurorestorative aspects; and (iii) the achievements and progresses
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clinical studies that are based on greater levels of evidence-based medical practices both
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in clinical therapies and clinical trials based on standard designs.

Introduction

of neurorestorative function, and clinical therapies
based on neurorestorative principals.

Little drops of water, little grains of sand, make the mighty
ocean and the pleasant land. —Julia Carney.
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The Neurorestoratology is one of the frontiers of
neuroscience and neuro-medicine disciplines. To make
readers aware and to follow the developments in
the field every year, we have initiated publishing
the Yearbooks recently that is acclaimed among the
neurorestorative communities worldwide. Accordingly,
the 2018 Neurorestorative Yearbook summarizes the
major progresses and achievements of the year focusing
on pathogenesis of neurological diseases, mechanisms

Several studies support the cholinergic system failure
hypothesis in the development of Alzheimer’s disease
(AD) pathogenesis because cholinergic therapy either
slowed down or partially restored brain atrophy [1].
In addition, the tau pathology strongly connected
with the pathologic processes of AD. The tau deposition could damage the intrinsic neuronal network
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connectivity and spread further within the brain to
damage synaptic connection. With the increasing
tau burden in AD, the functional impairment and
weakening of the neuronal connectivity occurs in a
progressive manner leading to loss of function and
development of the disease [2]. Musi et al. found a
strong association between the presence of neurofibrillary tangle (NFTs) and cellular senescence
in the brain causing neurodegeneration [3]. This
pathological process may be implicated for a new
neurorestorative therapy for suitable AD treatment.
The study by Wei et al. demonstrated that exacerbating
oxidation of the voltage-gated K+ channel subfamily
B member 1(KCNB1) channels might be another key
factor in the pathogenesis of AD [4]. Gatt and coworkers
reported that patients with dementia associated with
Lewy bodies (DLB) in AD and/or in Parkinson disease
dementia (PDD) exhibited 2-fold increase in cortinpositive cells in the subgranular zone as compared to
non-demented controls subjects. They also found that
treatment with selective serotonin reuptake inhibitors
was associated with increased hippocampal neurogenesis and preservation of cognition in DLB/PDD
patients [5].
Hu et al. showed that the T-lymphocyte levels
in the peripheral blood were lower in Parkinson’s
disease (PD) than in healthy subjects. Treatment with
L-DOPA in PD patients resulted in higher levels of
T-lymphocytes in the peripheral blood as compared to
placebo. This is well known that the immune function
of T cells in patients with other severe neurological
disease are also lower in plasma [6].
Through integrating genomic fine mapping with
brain expression and chromosomal conformation
data, Pardiñas and colleagues identified the genes
within 33 loci was responsible for the pathogenesis of
schizophrenia [7].
Shi et al. showed that reducing chromosome 9 open
reading frame 72 (C9ORF72) expression by repeating
its expansion could trigger motor neurons’ degeneration
in patients with amyotrophic lateral sclerosis (ALS)
through accumulation of glutamate receptors that lead
to excitotoxicity and/or impaired clearance of neurotoxic
dipeptide repeat proteins derived from the repeat
expansion [8].
There are discrepancies in discoveries about
neurogenesis in human. Sorrells et al. reported that
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neurogenesis in the dentate gyrus does not continue,
or is extremely rare, in adult humans. The number of
proliferating progenitors and young neurons in the
dentate gyrus declines sharply during the first year
of life until 13 years of age [9]. One report by Boldrini
et al. demonstrates that similar numbers of intermediate
neural progenitors and neurons are present in the
dentate gyrus across the ages. On the other hand,
healthy older subjects without cognitive impairment
or neuropsychiatric disease keep neurogenesis and
sustained human-specific cognitive function throughout
the life [10]. These discrepancies in results suggest that
pathogenesis of neurodegenerative and psychological
diseases might be of different origin.

3

New mechanisms of neurorestorative
therapy

Intranasal mesenchymal stromal cell (MSC) treatment
significantly improved sensorimotor and mechanosensory function after 21 days of subarachnoid
hemorrhage (SAH) associated with a sharp decline in
SAH-induced activation of astrocytes and microglia/
macrophages in the affected hemisphere. This
suggests that SAH induced activation of microglia and
microphages could be reduced by treatment of stem
cells and indicates one of the functional neurorestorative
mechanisms [11].
Kunath et al. showed that the focal nature of
PARKIN-mediated neurodegeneration and lack of
active synucleinopathy in most young-onset cases
could make patients to be the ideal candidates for
dopaminergic cell replacement therapy. This is in
the line of a new neurorestorative mechanism using
genetically engineered grafts that are resistant to
synucleinopathy. It appears that this will improve the
outcome of cell replacement therapies for sporadic
PD cases [12].
Data of da Silva et al. showed that manipulations
of dopamine neuronal activity of the substantia nigra
pars compacta after initiation of motor activity did
not affect the ongoing motor functions [13]. Liu et al.
revealed that fast release of dopamine could provide
molecular machinery for functional regulations. These
findings will definitely advance the therapeutic
strategies for the patients of PD in future [14].
A study by Konermann et al. demonstrated that
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CasRx as a programmable RNA-binding module for
efficient targeting of cellular RNA in a neuronal model
of frontotemporal dementia. This enabled a general
platform for transcriptome engineering, which could
be a new neurorestorative mechanism for exploration
of future therapeutic strategy [15].
Pignatelli et al. reported that unknown transient
enhancement of context recognition was based on the
plasticity of engram cell excitability. This is a recall
of contextual memory that is influenced by previous
but recent activation of the same engram. The state
of excitability of engram cells mediates differential
behavioral outcomes upon memory retrieval. This
suggests that promoting adaptive behavior may be
important for survival [16].
Bussian et al. found cleaning up senescent astrocytes
and microglia could prevent gliosis, hyperphosphorylation of both soluble and insoluble tau, and
degeneration of cortical and hippocampal neurons.
This could be the basis of preserving cognitive
function [17].
Data by Bedrosian et al. elucidates that increasing
the amount of maternal care can block the accumulation of long interspersed nuclear element-1 (L1).
This early life experience drives somatic variation in
the genome via L1 retrotransposons. This discovery
implicates to treat certain disease of the children such
as Autism through mothers’ more love and care [18].

4

4.1

New achievements and progresses in
clinical neurorestorative therapies
Cell therapy

Levi et al. conducted a multi-center single blind,
randomized clinical study of human neural stem cell
transplantation into the cervical spinal cord in patients
with chronic C5-7 tetraplegia. They found that after
1-year post-transplantation, the procedures of cell
therapy were safe, well tolerable, and feasible and
resulted in a trend towards motor sensibility gains
in the treated subjects [19]. Further research by
Guadalajara et al. showed that a 58-year-old man
with an incomplete spinal cord injury (SCI) secondary
to L1 vertebral fracture, presented gait disorder
with neurogenic bowel and bladder dysfunction. He
received autologous mesenchymal stromal cells in the

subarachnoid space by lumbar puncture. This patient
had significant improvement in almost every functional
scale of SCI [20]. Vaquero et al. reported a phase 2
clinical trial in patients with chronic SCI that received
three intrathecal administrations of MSCs. In this study,
patients showed varied clinical improvement in sensitivity, motor power, spasms, spasticity, neuropathic
pain, sexual function and/or sphincter dysfunction
during the follow-up [21]. This treatment was also
well tolerated without any adverse event-related to
MSC administration. Vaquero et al. further presented
a phase 2 clinical trials that has six paraplegic patients
with post-traumatic syringomyelia that received
MSCs inside the syrinx [22]. These patients achieved
reduction of syrinx and clinical improvements in
motor function, sensation, neurogenic urodynamic
and bowel dysfunction and spasticity with a follow-up
for 6 months in different degrees of improvements.
Vaquero et al. reported that intrathecal administration
of autologous MSCs could improve progressively or
relieve neuropathic pain intensity in SCI patients
during 10 months’ follow-up [23]. Data by Santamaría
et al. showed results in a female subject with complete
C2 SCI who received bone marrow derived MSC
through intrathecal infusions. After 14 months’ postinjury, she exhibited deep inspiratory maneuvers
triggered respiratory-like EMG bursting in the biceps
and several other muscles [24]. Gustavo et al. reported
that the combination of immune and regenerative cell
therapy could restore chronic muscular atrophy in
clinical and histological examination in patients with
severe muscular atrophy because of chronic complete
SCI [25]. Al Kandari et al. followed up nine patients
with chronic SCI that underwent cell transplantation
therapies from China, Egypt, Germany, India, and
Iran; but didn’t find clinical useful improvements
in sensorimotor, autonomic, or functional status in
individuals after cell therapy [26].
Liem et al. reported that bone marrow-derived
mononuclear cells transplantation could improve
bowel function in 2 children with spina bifida after
myelomeningocele repair [27].
Sung et al. examined the effects of transfusion of
circulatory-derived autologous CD34+ cells into the
intra-carotid artery of the ipsilateral brain infarct area
in old ischemic stroke patients. Their results showed
that procedure of CD34+ cell therapy was safe and
Journal of Neurorestoratology
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might offer some benefits to old ischemic stroke
patients [28]. A study by Savitz and coworkers revealed
that delivering autologous bone marrow derived
ALD-401 through internal carotid artery infusion for
patients with disabling middle cerebral artery subacute
stroke was safe, but didn’t show significant functional
improvement compared to sham-harvest with shaminfusion [29]. Laskowitz et al. conducted a phase I
open-label trial, which showed that a single i.v. dose
of allogeneic non-HLA matched human umbilical
cord blood cells was safe and improved some of the
neurological functions in 10 patients with acute middle
cerebral artery ischemic stroke [30].
van Horne et al. reported that peripheral nerve graft
within the substantia nigra at the time of deep brain
stimulation (DBS) surgery was feasible, safe and had
some clinical benefits for patients in PD [31].
Nguyen et al. reported that the autologous bone
marrow mononuclear cells improved quality of life in
30 children with cerebral palsy (CP) after 6 months
of transplantation through intrathecal infusions [32].
This was accompanied with improvements in gross
motor function and muscle tone. Elena et al. showed
that cell therapy based on M2 macrophages was safe
and significantly improved neurologic functions in
patients with severe CP [33].
da Cruz et al. successfully delivered the retinal
pigment epithelium patch for two patients with agerelated macular degeneration. The epithelium patch
survived well and associated with patients’ visual
acuity improvement during 12 months’ follow-up
study [34].
Mao et al. showed their clinical study of a multicenter,
randomized, double-blinded, placebo-controlled trial
of olfactory ensheathing cells and Schwann cells to
test two kinds of neurorestorative effect for patients
with sub-acute and chronic ischemic stroke [35]. Phan
et al. report their design of phase 1 trial of human
amniotic epithelial cells (hAECs) for ischemic stroke
that assesses the safety of allogeneic hAECs [36]. Deng
et al. publish their design of a prospective, randomized,
controlled, observer-blinded phase II trial to assess
the clinical safety and feasibility of allogenic bone
marrow-derived MSCs by intrathecal infusion in
patients with ischemic stroke due to cerebral infarction
within the middle cerebral artery [37]. Osanai et al.
report the design, which is a randomized, double-blind,

11
placebo-controlled, multicenter for MultiStem®-one kind
of allogenic cell products cell products in patients
with acute (within 18–36 h of stroke onset) ischemic
stroke. Its aim is to obtain stronger evidence and to
show the efficacy of MultiStem® for treatment of
ischemic stroke [38].
Garitaonandia et al. report that International Stem
Cell Corporation’s (ISCO’s) will conduct a singlecenter, open label, dose escalating 12-month study
with a 5-year follow-up evaluating the safety and
efficacy of a novel human parthenogenetic derived
neural stem cell in PD patient [39].
Loring reports that an autologous cell therapy is
entering the regulatory approval process in 2018 with
the U.S. Food and Drug Administration, and will begin
to transplant the cells within 1 to 2 years [40].
4.2 Neurostimulation/neuromodulation and the
brain-computer interface (BCI)
Cichoń et al. reported extremely low-frequency
electromagnetic field therapy could improve the
effectiveness of rehabilitation for post-stroke patients
through significantly increased growth factors, cytokine
levels and gene expression on the mRNA level.
This could be another new mechanism of functional
neurorestoration [41].
Implanted electrodes for electrical stimulation with
intensive neurorehabilitation could partially restored
standing and walking abilities in patients with complete
chronic SCI [42,43]. In such cases, improved reflexive
voiding efficiency [44], enhanced cardiovascular fitness
and body composition [45], better neurological recovery
[46] that supported the activities of daily living [47],
and reduced that elevated blood pressures to normal
ranges from a chronic hypotensive state [48] were
observed.
Poiani and colleagues report that a design of a
randomized double-blinded trial of photobiomodulation using low-level laser therapy (LLLT) could be an
effective low-cost treatment for patients with traumatic
brain injury (TBI). The results were evaluated to see
whether LLLT could improve or restore cognitive
sequel after TBI [49]. Santos et al. published a design
of a double-blinded, randomized, controlled trial of
patients with diffuse axonal injury due to a severe TBI
in an acute stage. They evaluated whether early and
delayed effects of transcranial light-emitting diodes
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therapy could improve or restore the cognitive function
and promote beneficial hemodynamic changes in
cerebral circulation [50].
da Silva et al. presented a design of a randomized,
controlled, double-blind, clinical trial for photobiomodulation in the sublingual region for multiple
sclerosis (MS). The neurorestorative mechanisms
for photobiomodulation may include neurogenesis,
reducing nitric oxide levels, and regulating the cytokine
IL10 and thereby inducing neuroprotection [51].
4.3

Neurorestorative surgery

Falci et al. performed dorsal root entry zone lesion
of the spinal cord caudal to the level of complete
spinal cord transection could completely or nearcompletely relieve all below-level neuropathic pain
in 3 patients but failed to relieve their SCI induced
central pain [52].
Intramedullary decompression under microscope
and decompression laminectomy with duroplasty
can benefit for patients with acute complete SCI in
improving their neurological functions. But these
procedures need to be confirmed by clinical trial of a
multicenter, randomized, double blind placebo-control
of intramedullary decompression. The design of a
clinical trial of intramedullary decompression will
explore the safety and neurorestorative effects in
patients with acute complete spinal cord contusion
injury [53].
4.4

Pharmaceutical neurorestorative therapy

Evidence from Ko et al. demonstrated that acidic
fibroblast growth factor directly applied to the injured
spinal cord in 48 patients with chronic SCI was safe,
feasible, and could yield modest functional improvement after 48 months of follow-up study [54].
Granulocyte-colony stimulating factor (GCSF) had
some benefits in cases of incomplete subacute and
chronic SCI in some studies of double-blind randomized
controlled clinical trials [55, 56].
McDonald et al. reported placebo-controlled phase 2
trial of Drisapersen for Duchenne muscular dystrophy.
They found that Drisapersen 6 mg/kg/week resulted
in a treatment benefit of 6-minute walking distance
that is largely maintained up to 24 weeks after
discontinuation of the therapy [57].
Panza et al. showed the trial design to evaluate

whether solanezumab and gantenerumab could prevent
AD in its early onset for people with autosomaldominant AD or cognitively healthy subjects at risk
of developing sporadic AD [58].
4.5

Bioengineering and tissue engineering therapy

Strauss et al. reported that intrathecal antisense
oligonucleotide (nusinersen) therapy was relatively
safe and well tolerated in spinal muscular atrophy
(SMA) patients with advanced disease and spinal
fusion [59].
Eckstein et al. described that rituximab was used
to treat 8 patients with langerhans cell histiocytosis
and neurologic dysfunction resulted in some clinical
improvement that included gait abnormalities, tremors,
proprioceptive deficits, dysarthria/dysphagia and
intellectual/behavioral/psychological symptoms [60].
Kucher et al. found that human anti-Nogo-A
antibody was well tolerated in patients with acute
complete SCI through intrathecal administration and
showing some efficacy [61].
4.6

Other therapies

Hubscher et al. found that locomotor training could
improve bladder, bowel and sexual function in patients
with chronic SCI [62]. Sandroff et al. published a
design of a single-blind, randomised controlled trial of
exercise training for managing learning and memory
impairment and evaluated whether this therapy
could improve cognition in patients with multiple
sclerosis [63].
4.7

Guidelines

Trento et al. showed large heterogeneity regarding
product specification, particularly in the markers used
for phenotypical characterization and their threshold
of expression. Thus, use of potency assays to MSC
functionality, and karyotyping aside from variations in
the culture method is needed in order to standardize
the MSC product as a clinical therapeutic tool. For
this, it is needed to set up the standard of cell culture
and quality control to keep cells more homogeneous
that may reduce variability and could be easier to
interpret results in clinical trials from different
centers [64].
It should be noted that several authors often
misused this identification standard of MSCs to that
Journal of Neurorestoratology
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of mesenchymal stem cells. The criteria of MSCs
developed by the International Society for Cellular
Therapy include (1) MSC must be plastic-adherent
when maintained in standard culture conditions;
(2) MSC must express CD105, CD73 and CD90, and lack
expression of CD45, CD34, CD14 or CD11b, CD79alpha
or CD19 and HLA-DR surface molecules; and (3) MSC
must differentiate to osteoblasts, adipocytes and
chondroblasts in vitro [65–67].
In this regards, Chinese Association of Neurorestoratology sets the standards of the culture and quality
control of umbilical cord MSCs and neural progenitor/
precursor cells that were used in neurorestorative
clinical application in 2017 [68, 69].
International Association of Neurorestoratology
and the Chinese Association of Neurorestoratology
proposed clinical cell therapy guidelines for neurorestoration, which included items of cell type
nomenclature, cell quality control, minimal suggested
cell doses, informed patients consent, indications
and contraindications for undergoing cell therapy,
documentation of procedure and therapy, safety &
efficacy evaluations, policy of repeated treatments, no
cost to patients for unproven therapies, basic principles
of cell therapy, and publishing responsibility [70].
Based on established medical, engineering and
scientific principles, Bikson et al. outlined a robust
and transparent technical framework for ensuring
limited output transcranial electrical stimulation devices,
which are designed to minimize risks, while also
supporting access and innovation could be a new
beginning in neurorestorative therapy for the benefit
of patients [71].

5

Summary

In 2018, the trend in global clinical research revealed
that there are rigorous and high levels of evidencebased medical practice in ongoing or completed clinical
trials and/or upcoming clinical trial designs. This will
undoubtedly provide greater benefits to patients from
neurorestorative therapies.

Disclosure
The authors declare that they have no competing
interests.
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